Opinion|Videos|September 4, 2024
Navigating SG-related Diarrhea
Panelists discuss how to manage sacituzumab govitecan therapy, including absolute neutrophil count cutoffs for dose adjustments, handling febrile neutropenia, comparing diarrhea rates to clinical trials, identifying risk factors, and strategies for managing SG-related diarrhea.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please comment on your absolute neutrophil count cutoff for dose reductions and/or delay of sacituzumab govitecan (SG) therapy.
- How do you manage subsequent doses for patients who experienced febrile neutropenia with the previous cycle?
- How often do you see diarrhea (associated with SG) in your clinical practice? How does it compare to the rates reported in clinical trials (ASCENT, TROPiCS-02)?
- Are there risk factors that can predict those who are at higher risk for developing diarrhea?
- Are there any situations where you would consider testing for UGT1A1*28 homozygosity?
- Please comment on how you typically manage SG-related diarrhea.
- Are you utilizing prophylactic atropine or loperamide to prevent cholinergic syndrome prior to Cycle 1 of SG?
- Please comment on your management strategy for SG-related diarrhea (any similarities vs differences).
Advertisement
Related to this article
The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ESR1 mutation.
GLP-1 receptor agonists are generating buzz for their metabolic benefits, as well as for their potential to directly combat breast cancer progression.
T-DXd plus pertuzumab was approved in the European Union as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The sNDA is supported by VIKTORIA-1 Study 2 data showing that gedatolisib-based regimens approximately doubled median PFS vs alpelisib plus fulvestrant.
The European Commission approved sacituzumab govitecan plus pembrolizumab for treatment-naive, PD-L1–positive, metastatic triple-negative breast cancer.
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL
5